Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 3/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381200 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL8318189 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL5386518 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL9776388 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL5388151 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL1405659 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL3033191 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL5393795 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL8321457 | 0.97 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL3480698 | 0.94 | DNM1 (0.43) | DNM1TSHRTHRBKDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4152910-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Kyulux, Inc. (JP) | 2023-03-22 | — | — | EP | claimed |
| US-11944010-B2 | Organic electroluminescent device | KYULUX, INC. (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4152910-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Kyulux, Inc. (JP) | 2023-03-22 | — | — | EP | disclosed |
| EP-3171421-B1 | ORGANIC LIGHT-EMITTING ELEMENT | UNIV KYUSHU NAT UNIV CORP (JP) | 2023-01-25 | — | — | EP | disclosed |
| US-20210074927-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | KYULUX, INC. (JP) | 2021-03-11 | — | — | US | disclosed |
| US-10862047-B2 | Organic electroluminescent device | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2020-12-08 | — | — | US | disclosed |
| EP-3706182-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Kyushu University National University Corporation (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-10658596-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| US-10600983-B2 | Organic electroluminescent device comprising delayed fluorescent materials | KYULUX, INC. (JP) | 2020-03-24 | — | — | US | disclosed |
| US-10559757-B2 | Host material for delayed fluorescent materials, organic light-emitting device and compound | KYULUX, INC. (JP) | 2020-02-11 | — | — | US | disclosed |
| US-20150037813-A1 | ANTIBODY AGAINST AFFINITY COMPLEX | FUJIREBIO INC. (JP) | 2015-02-05 | — | — | US | disclosed |
| EP-2759551-A1 | ANTIBODY AGAINST AFFINITY COMPLEX | Fujirebio Inc. (JP) | 2014-07-30 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7956182-B2 | Process for preparing optically active alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988071-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE ALCOHOL | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10559757-B2 | Host material for delayed fluorescent materials, organic light-emitting device and compound | TERB1, TERT, TCOF1 | DNM1 3940/4885TSHR 1118/4885THRB 727/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | DNM1 1442/4885TSHR 319/4885THRB 488/4885 |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | ADH1C, ADH1A, ADH5 | DNM1 1351/4885TSHR 651/4885THRB 1117/4885 |
| US-20150037813-A1 | ANTIBODY AGAINST AFFINITY COMPLEX | FCGR3B, FCGR2A, FCGR1A | DNM1 3429/4885TSHR 1633/4885THRB 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.